Home › Leucemia mieloide acuta › New Jersey
Studi clinici su Leucemia mieloide acuta nello stato di New Jersey
32 studi su Leucemia mieloide acuta cercano partecipanti presso sedi nello stato di New Jersey.
Città nello stato di New Jersey
- Edison20 studi
- Clifton12 studi
- Newark12 studi
- Paterson7 studi
- Brick7 studi
- Toms River5 studi
- Camden4 studi
Testo ufficiale dello studio (inglese)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Englewood Hospital and Medical Center, Englewood
- Hackettstown Medical Center, Hackettstown
- Morristown Medical Center, Morristown
- e altri 6
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 40 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05334069Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
- e altri 1
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06484062A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
In reclutamentoFase 1
Età da 12 a 78 · Tutti i sessi · Aggiornato il 29 set 2026 · NCT03802695Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Cooperman Barnabas Medical Center, Livingston
- Monmouth Medical Center, Long Branch
- e altri 6
In reclutamentoFase 2
Età da 18 a 59 · Tutti i sessi · Aggiornato il 28 set 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Cooper Hospital University Medical Center, Camden
- Cooperman Barnabas Medical Center, Livingston
- e altri 7
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Cooperman Barnabas Medical Center, Livingston
- Monmouth Medical Center, Long Branch
- e altri 6
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06317649A Study of CRD3874-SI in People With Leukemia
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All protocol activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07661095Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Cooperman Barnabas Medical Center, Livingston
- Monmouth Medical Center, Long Branch
- e altri 4
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Cooper Hospital University Medical Center, Camden
- Cooperman Barnabas Medical Center, Livingston
- e altri 7
In reclutamentoFase 2
Età da 18 a 59 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Hackensack University Medical Center, Hackensack
- Morristown Medical Center, Morristown
- Jersey Shore Medical Center, Neptune City
- e altri 4
In reclutamentoFase 3
6 Months – 21 Years · Tutti i sessi · Aggiornato il 17 set 2026 · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- John Theurer Cancer Center at Hackensack UMC, Hackensack
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT06824168Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Atlantic Health, Morristown
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT04588922The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Hackensack University Medical Center, Hackensack
- Morristown Medical Center, Morristown
- Jersey Shore Medical Center, Neptune City
- e altri 3
In reclutamentoFase 1/2
Fino a 22 anni · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Hackensack University Medical Center, HMH, Hackensack
- Morristown Medical Center, Morristown
In reclutamentoFase 3
29 Days – 21 Years · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Rutgers Biomedical and Health Sciences, New Brunswick
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 ago 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 ago 2026 · NCT06001788A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)
- MDA at Cooper University Health Care, Camden
In reclutamentoFase 1 iniziale
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT07771803L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- Atlantic Health, Morristown
In reclutamentoFase 2/3
Età da 18 a 80 · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT06788756A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
- Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
In reclutamentoFase 2
Età 60 e oltre · Tutti i sessi · Aggiornato il 17 lug 2026 · NCT07392242Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 lug 2026 · NCT07216443A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Hackensack University Medical Center, Hackensack
- Robert Wood Johnson/Cancer Institute of New Jersey, New Brunswick
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT01351545A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 giu 2026 · NCT05756777A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
In reclutamentoFase 1
Età 1 e oltre · Tutti i sessi · Aggiornato il 22 giu 2026 · NCT06017258A Study of Revumenib and Mezigdomide in People With Leukemia
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 22 giu 2026 · NCT07356154A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
In reclutamentoFase 1
Età da 18 a 70 · Tutti i sessi · Aggiornato il 17 giu 2026 · NCT07011004A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- John Theurer Cancer Center / Hackensack University, Hackensack
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 apr 2026 · NCT04256317A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Atlantic Health, Morristown
- Rutgers Cancer Institute of New Jersey, New Brunswick
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 24 mar 2026 · NCT04988555Phase IB/II of CPX-351 for Relapse Prevention in AML
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 mar 2026 · NCT04990102A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Hackensack University Medical Center, Hackensack
- Rutgers Cancer Institute, New Brunswick
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 mar 2026 · NCT05735184A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 mar 2026 · NCT05748197A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
- Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 feb 2026 · NCT06773208Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.